Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

CollPlant Biotechnologies (CLGN) Research & Development (2017 - 2025)

Historic Research & Development for CollPlant Biotechnologies (CLGN) over the last 9 years, with Q3 2025 value amounting to $2.1 million.

  • CollPlant Biotechnologies' Research & Development fell 2718.72% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year decrease of 2106.45%. This contributed to the annual value of $10.5 million for FY2024, which is 29.57% up from last year.
  • As of Q3 2025, CollPlant Biotechnologies' Research & Development stood at $2.1 million, which was down 2718.72% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, CollPlant Biotechnologies' Research & Development registered a high of $3.1 million during Q4 2023, and its lowest value of $1.6 million during Q1 2021.
  • For the 5-year period, CollPlant Biotechnologies' Research & Development averaged around $2.4 million, with its median value being $2.4 million (2024).
  • Data for CollPlant Biotechnologies' Research & Development shows a peak YoY increase of 10160.49% (in 2021) and a maximum YoY decrease of 9979.28% (in 2021) over the last 5 years.
  • Over the past 5 years, CollPlant Biotechnologies' Research & Development (Quarter) stood at $2.2 million in 2021, then increased by 20.47% to $2.6 million in 2022, then increased by 18.05% to $3.1 million in 2023, then decreased by 18.31% to $2.5 million in 2024, then dropped by 17.85% to $2.1 million in 2025.
  • Its Research & Development stands at $2.1 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.1 million for Q1 2025.